Getsios D - Search Results

1

Economic assessments of low molecular weight heparin in venous thromboembolism.

Ward A, Getsios D, O'Brien J, Caro JJ. Ward A, et al. Among authors: getsios d. Expert Rev Pharmacoecon Outcomes Res. 2004 Feb;4(1):39-47. doi: 10.1586/14737167.4.1.39. Expert Rev Pharmacoecon Outcomes Res. 2004. PMID: 19807334

2

Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis.

Caro JJ, Getsios D, Caro I, O'Brien JA. Caro JJ, et al. Among authors: getsios d. Pharmacoeconomics. 2002;20(9):593-602. doi: 10.2165/00019053-200220090-00003. Pharmacoeconomics. 2002. PMID: 12141887

3

Managing meningococcal disease in the United States: Hospital case characteristics and costs by age.

O'Brien JA, Caro JJ, Getsios D. O'Brien JA, et al. Among authors: getsios d. Value Health. 2006 Jul-Aug;9(4):236-43. doi: 10.1111/j.1524-4733.2006.00113.x. Value Health. 2006. PMID: 16903993 Free article.

4

Pharmacoeconomic evidence and considerations for triptan treatment of migraine.

Caro JJ, Getsios D. Caro JJ, et al. Among authors: getsios d. Expert Opin Pharmacother. 2002 Mar;3(3):237-48. doi: 10.1517/14656566.3.3.237. Expert Opin Pharmacother. 2002. PMID: 11866674 Review.

5

Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.

Garfield FB, Getsios D, Caro JJ, Wimo A, Winblad B. Garfield FB, et al. Among authors: getsios d. Pharmacoeconomics. 2002;20(9):629-37. doi: 10.2165/00019053-200220090-00006. Pharmacoeconomics. 2002. PMID: 12141890

6

Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.

Caro JJ, Salas M, Ward A, Getsios D, Mehnert A; AHEAD Study Group. Assessment of Health Economics in Alzheimer's Disease. Caro JJ, et al. Among authors: getsios d. Dement Geriatr Cogn Disord. 2002;14(2):84-9. doi: 10.1159/000064929. Dement Geriatr Cogn Disord. 2002. PMID: 12145455

7

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G; AHEAD Study Group. Migliaccio-Walle K, et al. Among authors: getsios d. Clin Ther. 2003 Jun;25(6):1806-25. doi: 10.1016/s0149-2918(03)80171-6. Clin Ther. 2003. PMID: 12860500 Clinical Trial.

8

Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F. Caro J, et al. Among authors: getsios d. Drugs Aging. 2004;21(10):677-86. doi: 10.2165/00002512-200421100-00005. Drugs Aging. 2004. PMID: 15287825

9

Economic burden of pertussis and the impact of immunization.

Caro JJ, Getsios D, Payne K, Annemans L, Neumann PJ, Trindade E. Caro JJ, et al. Among authors: getsios d. Pediatr Infect Dis J. 2005 May;24(5 Suppl):S48-54. doi: 10.1097/01.inf.0000160929.35004.86. Pediatr Infect Dis J. 2005. PMID: 15876924 Review.

10

Pertussis immunization of adolescents in the United States: an economic evaluation.

Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien JA. Caro JJ, et al. Among authors: getsios d. Pediatr Infect Dis J. 2005 May;24(5 Suppl):S75-82. doi: 10.1097/01.inf.0000160918.72953.51. Pediatr Infect Dis J. 2005. PMID: 15876932

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters